The company said net sales for Q3 2024 were $4.209 billion, up 19.4% on a reported basis and 18.2% on an organic basis from the prior-year period. The company's prior guidance range was 13 to 15% on both a reported and organic basis.

1. 01

   The company said net sales for Q3 2024 were $4.209 billion, up 19.4% on a reported basis and 18.2% on an organic basis from the prior-year period. The company's prior guidance range was 13 to 15% on both a reported and organic basis.

2. 02

   Boston Scientific said GAAP net income attributable to its common stockholders for Q3 2024 was $469 million, or $0.32 per share, lower than $505 million, or $0.34 per share, a year earlier. It said adjusted EPS was $0.63, compared with $0.50 a year earlier.

3. 03

   The company said net sales for Q3 2024 rose 25.0% on a reported basis in its Cardiovascular segment and 10.3% in its MedSurg segment, compared with the prior-year period. By region, it said net sales grew 23.5% in the U.S., 15.2% in EMEA and 12.1% in APAC.

4. 04

   Boston Scientific said it expects full-year 2024 net sales growth of about 16.5% on a reported basis and adjusted EPS of $2.45 to $2.47. For Q4, the company expects net sales growth of about 16.5 to 18.5% on a reported basis and adjusted EPS of $0.64 to $0.66.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.